AZN AstraZeneca PLC
18,339
$76.12
$0.36
(0.47%)
| Watchers | 18,339 |
| 52-Wk Low | $60.47 |
| 52-Wk High | $76.80 |
| Market Cap | $234.89B |
| Volume | 1.25M |
| 52-Wk High | $76.80 |
| 52-Wk Low | $60.47 |
Systematic Review Reveals Many COVID-19 Vaccine Recipients Experienced New-Onset PsychosisZero Hedge • about 7 hours ago
Systematic Review Reveals Many COVID-19 Vaccine Recipients Experienced New-Onset Psychosis
Authored by Naveen Athrappully via The Epoch Times (emphasis ours),
Individuals who took...
Share to Feed
Top Five Cancer Types Dominate New US Cases as Biotech Sector Eyes $314B Market by 2032 Top Five Cancer Types Dominate New US Cases as Biotech Sector Eyes $314B Market by 2032 PR Newswire VANCOUVER...
Positive high-level results from an interim analysis of the ECHO Phase III trial showed AstraZenecas CALQUENCE (acalabrutinib) in combination with standard-of-care chemoimmunotherapy, bendamustine...
Study Finds Elevated Risk Of Eye Inflammatory Disorder Following COVID-19 Vaccination
Authored by Megan Redshaw, J.D. via The Epoch Times (emphasis ours),
People with a history of...
AstraZeneca will showcase new clinical and real-world data across its leading inhaled, biologic and early science respiratory portfolio at the American Thoracic Society (ATS) International...
The agency sent letters to Novo Nordisk, AstraZeneca, Boehringer Ingelheim, Covis Pharma, GlaxoSmithKline, Novartis, Teva Pharmaceuticals, among others...
Discover the latest on AstraZeneca's Covid vaccine lawsuit. Allegations of serious side effects, including fatalities and brain injuries, spark legal battles. Learn about the controversy and...
Results from AstraZeneca's Enhertu trial vs. chemotherapy in HR-positive, HER2-low metastatic breast cancer.
read more...
Positive high-level results from the DESTINY-Breast06 Phase III trial showed that ENHERTU (fam-trastuzumab deruxtecan-nxki) demonstrated a statistically significant and clinically meaningful...
AstraZeneca CEO talks blowout earnings, global growth, new drugs, and pricing...